抗鱼精蛋白/肝素抗体与抗PF4/肝素抗体的血清学特征
本研究开发了针对鱼精蛋白/肝素复合物的鼠单克隆抗体ADA,并与患者来源的抗鱼精蛋白/肝素抗体及抗PF4/肝素抗体进行比较。结果显示抗鱼精蛋白/肝素抗体在广泛肝素浓度(0-50 U/mL)下保持结合,对细胞相关GAGs结合可变,且与PRT/葡聚糖结合密切关联细胞表面PRT结合能力,提示两类肝素依赖性抗体存在重要血清学差异。
要点
- 抗鱼精蛋白/肝素抗体在0-50 U/mL肝素浓度下保持与PRT/肝素结合。
- HIT抗体与PF4/肝素结合可被低剂量肝素(0-1 U/mL)抑制。
- 抗PRT/肝素抗体与PRT/葡聚糖结合与其结合细胞表面PRT的能力密切相关。
核心结论
- HIT抗体与抗鱼精蛋白/肝素抗体之间存在重要血清学差异,可能解释两类肝素依赖性抗体疾病表现的不同。
研究设计与样本
- 开发针对鱼精蛋白/肝素复合物的鼠单克隆抗体ADA,并与患者来源的抗鱼精蛋白/肝素抗体及抗PF4/肝素抗体进行比较。
主要发现
- HIT抗体与PF4/肝素结合可被低剂量肝素(0-1 U/mL)抑制,而抗鱼精蛋白/肝素抗体(包括ADA)在广泛肝素浓度(0-50 U/mL)下保持与PRT/肝素结合。
- 抗PF4/肝素抗体识别与纯化或细胞相关GAGs复合的PF4,而抗鱼精蛋白/肝素抗体对细胞相关GAGs显示可变结合。
- 抗鱼精蛋白/肝素抗体与PRT/葡聚糖复合物的结合与其结合细胞表面PRT的能力密切相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Anti-protamine (PRT)/heparin antibodies are a newly described class of heparin-dependent antibodies occurring in patients exposed to PRT and heparin during cardiac surgery. To understand the biologic significance of anti-PRT/heparin antibodies, we developed a murine monoclonal antibody (ADA) specific for PRT/heparin complexes and compared it to patient-derived anti-PRT/heparin antibodies, as well as comparing polyclonal and monoclonal antibodies with anti-platelet factor 4 (PF4)/heparin. Using monoclonal antibodies and polyclonal patient-derived antibodies, we show distinctive binding patterns of anti-PRT/heparin antibodies as compared with PF4/heparin antibodies. Whereas heparin-induced thrombocytopenia (HIT) antibody binding to PF4/heparin is inhibited by relatively low doses of heparin (0-1 U/mL), anti-PRT/heparin antibodies, including ADA, retain binding to PRT/heparin over a broad range of heparin concentrations (0-50 U/mL). Unlike PF4/heparin antibodies, which recognize PF4 complexed to purified or cell-associated glycosaminoglycans (GAGs), anti-PRT/heparin antibodies show variable binding to cell-associated GAGs. Further, binding of anti-PRT/heparin antibodies to PRT/dextran complexes correlates closely with the ability of antibodies to bind to cell-surface PRT. These findings suggest that antibody binding to PRT/dextran may identify a subset of clinically relevant anti-PRT/heparin antibodies that can bind to cell-surface GAGs. Together, these findings show important serologic differences between HIT and anti-PRT/heparin antibodies, which may account for the variability in disease expression of the two classes of heparin-dependent antibodies.
引用
- Lee GM, Joglekar M, Kuchibhatla M, et al. Serologic characterization of anti-protamine/heparin and anti-PF4/heparin antibodies. Blood Adv. 2017. PMID: 29296706. doi:10.1182/bloodadvances.2017004408
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。